SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles.
Zhang T, Xu J, Yin J, Gao Y, Zheng H, Fu B, Sun J, Xu Z, Tu S, Mao Y, Wen W, Qu B, You L, Xue Z, Sun X, Cao D, Feng J, Hu M, He F.
Zhang T, et al. Among authors: mao y.
PLoS One. 2025 Jun 26;20(6):e0326691. doi: 10.1371/journal.pone.0326691. eCollection 2025.
PLoS One. 2025.
PMID: 40569929
Free PMC article.